Physician profile
Vikas Aurora
NPI 1033309240
$10,892.44
in general payments reported to CMS, 2019-2025
40 companies · $7,360 in 2025
The $7,360 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2021: $29.23 · 2022: $44.41 · 2023: $1,015 · 2024: $2,204 · 2025: $7,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,015 · Food and Beverage: $2,711 · Long Term Medical Supply Or Device Loan: $1,679 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,015.00 |
| Food and Beverage | $2,711.38 |
| Long Term Medical Supply Or Device Loan | $1,678.53 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $5,804.91 | 2025 | |
| Novartis Pharmaceuticals Corporation | $1,795.44 | 2023-2025 | |
| Beigene USA, INC. | $375.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $351.14 | 2019-2025 | Enhertu |
| Abbvie INC. | $263.90 | 2024-2025 | |
| Daiichi Sankyo INC. | $230.59 | 2023-2025 | Enhertu, Vanflyta |
| Merck Sharp & Dohme LLC | $164.03 | 2023-2025 | Keytruda, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $161.99 | 2022-2025 | Opdivo, Krazati, Eliquis |
| Gilead Sciences, INC. | $161.34 | 2021-2025 | Trodelvy |
| Pfizer INC. | $157.81 | 2019-2025 | |
| Celgene Corporation | $147.14 | 2023-2025 | Reblozyl |
| Incyte Corporation | $143.01 | 2023-2025 | Monjuvi, Jakafi |
| Lilly USA, LLC | $107.88 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Eisai INC. | $99.90 | 2022-2025 | |
| Janssen Biotech, INC. | $89.70 | 2024-2025 | Erleada, Tecvayli, Talvey |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Aurora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.